|previous article in this issue||next article in this issue|
Document Details :
Title: Apoliprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)
Author(s): MAITLAND-VAN DER ZEE, Anke-Hile , JUKEMA, J. Wouter , ZWINDERMAN, Aeilko H. , HALMANN, D. Michael , DE BOER, Anthonius , KASTELEIN, John J.P. , DE KNIJFF, Peter
Journal: Acta Cardiologica
Volume: 61 Issue: 3 Date: June 2006
Objective — The influence of ApoE polymorphism on the efficacy of statins in lowering plasma lipids and lipoproteins and improving angiographic parameters was assessed.
Methods — ApoE genotypes were studied in a group (n = 815) of well-characterised male coronary artery disease (CAD) patients who participated in the lipid-lowering regression study ‘Regression Growth Evaluation Statin Study (REGRESS)’.
Results — There was a significant interaction between treatment (placebo/pravastatin) and APOE genotype when lipid levels were considered, APOE2+ carriers exhibited the largest improvement of HDL levels (+0.15 mmol/l) and LDL/HDL ratios (-0.60) compared with APOE3+ (+0.06 mmol/l, -0.043, respectively) and APOE4 + carriers (+0.07 mmol/l,-0.040). In contrast, APOE2+ allele carriers had the least effect in terms of angiographic parameters,although the difference was not statistically significant.
Conclusions — The effects of statins in subjects with different ApoE genotypes were different with regard to the lipoprotein profile, but not with regard to angiographic parameters.